MA46373A - Composés utilisés comme modulateurs de ror gamma - Google Patents
Composés utilisés comme modulateurs de ror gammaInfo
- Publication number
- MA46373A MA46373A MA046373A MA46373A MA46373A MA 46373 A MA46373 A MA 46373A MA 046373 A MA046373 A MA 046373A MA 46373 A MA46373 A MA 46373A MA 46373 A MA46373 A MA 46373A
- Authority
- MA
- Morocco
- Prior art keywords
- mmr
- compounds used
- gamma modulators
- modulators
- gamma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461979231P | 2014-04-14 | 2014-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA46373A true MA46373A (fr) | 2019-08-07 |
Family
ID=52998264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA046373A MA46373A (fr) | 2014-04-14 | 2015-04-10 | Composés utilisés comme modulateurs de ror gamma |
Country Status (36)
Country | Link |
---|---|
US (5) | US9242989B2 (fr) |
EP (2) | EP3418280B1 (fr) |
JP (2) | JP6282759B2 (fr) |
KR (2) | KR102410069B1 (fr) |
CN (3) | CN107266454B (fr) |
AP (1) | AP2016009403A0 (fr) |
AR (2) | AR100058A1 (fr) |
AU (2) | AU2015247983B2 (fr) |
BR (2) | BR112016021962A2 (fr) |
CA (1) | CA2944787C (fr) |
CL (1) | CL2016002421A1 (fr) |
CY (1) | CY1122012T1 (fr) |
DK (1) | DK3131902T3 (fr) |
EA (2) | EA031351B1 (fr) |
ES (1) | ES2744299T3 (fr) |
HK (2) | HK1244800A1 (fr) |
HR (1) | HRP20191579T1 (fr) |
HU (1) | HUE045847T2 (fr) |
IL (2) | IL247419B (fr) |
LT (1) | LT3131902T (fr) |
MA (1) | MA46373A (fr) |
ME (1) | ME03513B (fr) |
MX (1) | MX370780B (fr) |
MY (1) | MY182834A (fr) |
NZ (1) | NZ723530A (fr) |
PE (2) | PE20161572A1 (fr) |
PH (2) | PH12016502019B1 (fr) |
PL (1) | PL3131902T3 (fr) |
PT (1) | PT3131902T (fr) |
RS (1) | RS59170B1 (fr) |
SG (1) | SG11201608537SA (fr) |
SI (1) | SI3131902T1 (fr) |
TW (2) | TWI655192B (fr) |
UA (2) | UA120094C2 (fr) |
UY (1) | UY36077A (fr) |
WO (1) | WO2015160654A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6282759B2 (ja) * | 2014-04-14 | 2018-02-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Rorガンマのモジュレーターとしての化合物 |
FR3030518B1 (fr) * | 2014-12-19 | 2018-03-23 | Galderma Research & Development | Derives sulfonamides en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t) |
ES2868175T3 (es) | 2015-05-15 | 2021-10-21 | Aurigene Discovery Tech Ltd | Compuestos de tetrahidroquinolinona sustituida como moduladores de ror gamma |
EP3356366B1 (fr) * | 2015-10-01 | 2019-08-28 | Boehringer Ingelheim International GmbH | Dérivés de ptéridine en tant que modulateurs de ror gamma |
CR20180328A (es) | 2015-12-15 | 2018-08-09 | Astrazeneca Ab | Compuestos de isoindol |
US11358967B2 (en) | 2016-01-20 | 2022-06-14 | Boehringer Ingelheim International Gmbh | Substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma |
AR110481A1 (es) | 2016-12-05 | 2019-04-03 | Lead Pharma Holding Bv | MODULADORES DE ROR g (RORg) |
US20200031753A1 (en) | 2017-04-06 | 2020-01-30 | Boehringer Ingelheim International Gmbh | Cyclopropyl alkyl amines and process for their preparation |
EP3638661A1 (fr) | 2017-06-14 | 2020-04-22 | Astrazeneca AB | 2,3-dihydroisoindole-1-carboxamides utiles en tant que modulateurs de ror-gamma |
CN109206346A (zh) * | 2017-07-01 | 2019-01-15 | 复旦大学 | 叔胺类衍生物或其盐及其制备方法和用途 |
CN107903263B (zh) * | 2017-12-28 | 2019-11-12 | 山东铂源药业有限公司 | 一种帕布昔利布中间体的合成方法 |
TWI818985B (zh) | 2018-05-03 | 2023-10-21 | 中國大陸商江蘇恒瑞醫藥股份有限公司 | 作為類視色素相關孤兒受體γ(RORγ)調節劑之苯并咪唑衍生物及其醫藥用途 |
EP3867224A1 (fr) | 2018-10-18 | 2021-08-25 | Boehringer Ingelheim International GmbH | Synthèse évolutive de 1-cyclopropylalkyl-1-amines optiquement actives |
US20230014730A1 (en) | 2019-09-23 | 2023-01-19 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Phosphodiesterase inhibitors and use |
US20220411380A1 (en) | 2019-10-31 | 2022-12-29 | Jiangsu Hengrui Medicine Co., Ltd. | ACID ADDITION SALT OF RORy REGULATOR |
WO2022106549A1 (fr) | 2020-11-19 | 2022-05-27 | Boehringer Ingelheim International Gmbh | Sels cristallins d'un inhibiteur de ror gamma |
WO2022106551A1 (fr) | 2020-11-19 | 2022-05-27 | Boehringer Ingelheim International Gmbh | Co-cristaux d'un inhibiteur de ror gamma |
WO2022106550A1 (fr) | 2020-11-19 | 2022-05-27 | Boehringer Ingelheim International Gmbh | Forme polymorphe cristalline d'un inhibiteur de ror gamma |
WO2022106548A1 (fr) | 2020-11-19 | 2022-05-27 | Boehringer Ingelheim International Gmbh | Formes solides d'un inhibiteur de ror gamma |
WO2022106547A1 (fr) | 2020-11-19 | 2022-05-27 | Boehringer Ingelheim International Gmbh | Procédé de synthèse d'un inhibiteur de ror gamma |
WO2023216910A1 (fr) * | 2022-05-07 | 2023-11-16 | 苏州浦合医药科技有限公司 | Composé hétéroaryle bicyclique substitué utile en tant qu'inhibiteur d'usp1 |
WO2023232870A1 (fr) | 2022-05-31 | 2023-12-07 | Immunic Ag | Modulateurs de rorg/rorgt pour le traitement d'infections virales de type covid-19 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0102716D0 (sv) * | 2001-08-14 | 2001-08-14 | Astrazeneca Ab | Novel compounds |
WO2009022185A2 (fr) * | 2007-08-16 | 2009-02-19 | Astrazeneca Ab | Composés chimiques - 795 |
PE20110854A1 (es) | 2008-09-26 | 2011-12-23 | Boehringer Ingelheim Int | DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1 |
EA021015B1 (ru) | 2009-10-21 | 2015-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Индазолы и пиразолопиридины в качестве антагонистов рецептора ccr1 |
EP2713736B1 (fr) * | 2011-06-01 | 2023-08-02 | Janus Biotherapeutics, Inc. | Nouveaux modulateurs du système immunitaire |
CN103930425B (zh) * | 2012-05-14 | 2016-04-27 | 华东理工大学 | 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用 |
JP6282759B2 (ja) * | 2014-04-14 | 2018-02-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Rorガンマのモジュレーターとしての化合物 |
EP3356366B1 (fr) * | 2015-10-01 | 2019-08-28 | Boehringer Ingelheim International GmbH | Dérivés de ptéridine en tant que modulateurs de ror gamma |
US11358967B2 (en) * | 2016-01-20 | 2022-06-14 | Boehringer Ingelheim International Gmbh | Substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma |
-
2015
- 2015-04-10 JP JP2016562565A patent/JP6282759B2/ja active Active
- 2015-04-10 BR BR112016021962A patent/BR112016021962A2/pt not_active IP Right Cessation
- 2015-04-10 MY MYPI2016001598A patent/MY182834A/en unknown
- 2015-04-10 SG SG11201608537SA patent/SG11201608537SA/en unknown
- 2015-04-10 UA UAA201610804A patent/UA120094C2/uk unknown
- 2015-04-10 NZ NZ723530A patent/NZ723530A/en unknown
- 2015-04-10 PL PL15718330T patent/PL3131902T3/pl unknown
- 2015-04-10 CN CN201710445005.9A patent/CN107266454B/zh active Active
- 2015-04-10 BR BR122020020657-8A patent/BR122020020657B1/pt active IP Right Grant
- 2015-04-10 PE PE2016001963A patent/PE20161572A1/es unknown
- 2015-04-10 EP EP18177902.6A patent/EP3418280B1/fr active Active
- 2015-04-10 SI SI201530865T patent/SI3131902T1/sl unknown
- 2015-04-10 EA EA201691978A patent/EA031351B1/ru not_active IP Right Cessation
- 2015-04-10 LT LTEP15718330.2T patent/LT3131902T/lt unknown
- 2015-04-10 PT PT15718330T patent/PT3131902T/pt unknown
- 2015-04-10 ME MEP-2019-233A patent/ME03513B/fr unknown
- 2015-04-10 PE PE2020001484A patent/PE20211002A1/es unknown
- 2015-04-10 EP EP15718330.2A patent/EP3131902B1/fr active Active
- 2015-04-10 KR KR1020167031654A patent/KR102410069B1/ko active IP Right Grant
- 2015-04-10 MX MX2016013342A patent/MX370780B/es active IP Right Grant
- 2015-04-10 UA UAA201803569A patent/UA121255C2/uk unknown
- 2015-04-10 CA CA2944787A patent/CA2944787C/fr active Active
- 2015-04-10 CN CN201710445827.7A patent/CN107266450B/zh active Active
- 2015-04-10 HU HUE15718330A patent/HUE045847T2/hu unknown
- 2015-04-10 AU AU2015247983A patent/AU2015247983B2/en not_active Ceased
- 2015-04-10 US US14/683,682 patent/US9242989B2/en active Active
- 2015-04-10 MA MA046373A patent/MA46373A/fr unknown
- 2015-04-10 AP AP2016009403A patent/AP2016009403A0/en unknown
- 2015-04-10 RS RSP20191083 patent/RS59170B1/sr unknown
- 2015-04-10 WO PCT/US2015/025328 patent/WO2015160654A1/fr active Application Filing
- 2015-04-10 CN CN201580016630.0A patent/CN106132965B/zh active Active
- 2015-04-10 KR KR1020207010364A patent/KR102410076B1/ko active IP Right Grant
- 2015-04-10 DK DK15718330.2T patent/DK3131902T3/da active
- 2015-04-10 EA EA201890329A patent/EA035063B1/ru not_active IP Right Cessation
- 2015-04-10 ES ES15718330T patent/ES2744299T3/es active Active
- 2015-04-13 AR ARP150101103A patent/AR100058A1/es not_active Application Discontinuation
- 2015-04-13 TW TW104111832A patent/TWI655192B/zh not_active IP Right Cessation
- 2015-04-13 UY UY0001036077A patent/UY36077A/es not_active Application Discontinuation
- 2015-04-13 TW TW107130729A patent/TWI652268B/zh not_active IP Right Cessation
- 2015-11-20 US US14/946,873 patent/US20160075706A1/en not_active Abandoned
-
2016
- 2016-08-22 IL IL247419A patent/IL247419B/en active IP Right Grant
- 2016-09-20 US US15/270,029 patent/US9598415B2/en active Active
- 2016-09-27 CL CL2016002421A patent/CL2016002421A1/es unknown
- 2016-10-11 PH PH12016502019A patent/PH12016502019B1/en unknown
-
2017
- 2017-01-23 HK HK18104172.2A patent/HK1244800A1/zh unknown
- 2017-01-23 HK HK18104174.0A patent/HK1244801A1/zh unknown
- 2017-02-07 US US15/426,208 patent/US20180022749A1/en not_active Abandoned
-
2018
- 2018-01-24 JP JP2018009384A patent/JP6463855B2/ja active Active
- 2018-09-06 US US16/123,139 patent/US20190002465A1/en not_active Abandoned
- 2018-12-20 IL IL26387818A patent/IL263878B/en active IP Right Grant
-
2019
- 2019-04-30 AU AU2019203027A patent/AU2019203027B2/en not_active Ceased
- 2019-09-02 HR HRP20191579 patent/HRP20191579T1/hr unknown
- 2019-09-09 CY CY20191100942T patent/CY1122012T1/el unknown
-
2020
- 2020-02-04 PH PH12020500252A patent/PH12020500252A1/en unknown
- 2020-07-21 AR ARP200102050A patent/AR119454A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA46373A (fr) | Composés utilisés comme modulateurs de ror gamma | |
IL290153A (en) | Tetrahydroquinolinone compounds are installed such as gamma modulators | |
IL268640B (en) | Transmuted imidazo quinolines as nlrp3 modulators | |
DK3394033T3 (da) | Heterocykliske forbindelser som immunmodulatorer | |
HK1254692A1 (zh) | 作為RORγ調節劑的新型化合物 | |
DK3341367T3 (da) | Bicyklisk-fusionerede heteroaryl- eller arylforbindelser som irak4-modulatorer | |
MA46760A (fr) | Modulateurs de ror gamma | |
HK1257756A1 (zh) | 作為RORγ調節劑的新型碳環化合物 |